AppLovin (APP) soars ~7% after blowout Q3 2025: revenue up 68%, buyback boosted by $3.2B, and Wedbush lifts price target to $800

AppLovin (APP) Slides on 11/11/2025 as Citi Trims Target; SEC Overhang Persists While Q3 Blowout and Axon Rollout Stay in Focus

Published: November 11, 2025


What’s new today

AppLovin Corporation (NASDAQ: APP) fell sharply in Tuesday trading, down roughly 7%–9% intraday to around $595–$605 as investors took profits following last week’s earnings pop and digested fresh sell‑side revisions. Real‑time market pages showed APP off more than 7% by early afternoon U.S. time. [1]

Citigroup nudged its 12‑month price target down to $820 from $850 while maintaining a Buy rating, a modest recalibration after the stock’s torrid run into and after Q3 results. [2]

Trade press continued to frame AppLovin as an AI‑powered ad‑tech winner relative to peers, with Digiday’s Tuesday Ad Tech Briefing highlighting investor preference for APP after recent beats. [3]


By the numbers: Q3 2025 (reported Nov. 5)

AppLovin posted a 68% year‑over‑year revenue jump to $1.405 billion for Q3 2025, with net income of $836 million and adjusted EBITDA of $1.158 billion. Management also guided Q4 revenue to $1.57–$1.60 billion and Q4 adjusted EBITDA to $1.29–$1.32 billion (82%–83% margin). The board lifted the company’s remaining share‑repurchase authorization to $3.3 billion as of the end of October. [4]


Today’s move in context

  • Profit‑taking after a surge: APP rallied on the earnings print and on ongoing enthusiasm for Axon, its AI‑driven ad stack. Tuesday’s pullback fits the pattern of post‑earnings digestion amid a choppier tech tape this week. Real‑time price trackers showed the stock down notably intraday. [5]
  • Incremental target change, not a thesis shift: Citi’s trim to $820 (Buy) landed alongside a raft of raised targets from other brokers last week, suggesting sentiment remains broadly constructive even as estimates normalize. [6]

Strategy watch: Axon Ads Manager expands, self‑serve

AppLovin rebranded its customer‑facing platform as Axon and launched Axon Ads Manager on Oct. 1 as a referral‑only, self‑service tool. The rollout aims squarely at performance advertisers who want an ROI‑first alternative to the walled gardens, with third‑party attribution and AI‑driven targeting central to the pitch. Industry reports note early traction among ecommerce brands and a phased onboarding plan through the holidays. [7]

Trade outlets and investor commentary over the past week have tied the stock’s strength to Axon’s execution and AppLovin’s operating leverage, themes that continue to underpin the bull case despite today’s drop. [8]


Regulatory backdrop: SEC probe still a swing factor

A U.S. SEC probe into AppLovin’s data‑collection practices—first reported Oct. 6—remains an overhang. The reporting emphasized that the company has not been accused of wrongdoing; nevertheless, the headlines initially knocked the shares double‑digits and continue to color risk perception. AppLovin has said it does not comment on potential regulatory matters and has retained external counsel to review short‑seller claims. [9]


Index milestone that broadened ownership

AppLovin joined the S&P 500 at the September quarterly rebalance, a milestone that typically expands passive fund ownership and lifts visibility among generalist investors. S&P Dow Jones Indices announced APP’s inclusion effective September 22, 2025. [10]


What to watch next

  • Q4 execution vs. high bar: After Q3’s beat and robust Q4 guide, investors will gauge whether holiday‑season ecommerce budgets flow into Axon at the pace implied by guidance. [11]
  • Regulatory clarity: Any update on the SEC review could materially reset risk premiums, up or down. [12]
  • Sell‑side models: Additional target tweaks—up or down—may follow as analysts digest the guide and the near‑term ad demand picture. Citi’s adjustment today is one such example. [13]

Bottom line

November 11, 2025 is shaping up as a consolidation day for APP: a notable pullback tied to broader tech volatility and a modest target trim, rather than a company‑specific operational miss. The core narrativeAxon‑powered growth, outsized operating leverage, and heavy buyback support—remains intact on the numbers, while the SEC probe is the known swing risk that keeps volatility elevated. For now, the stock’s setup hinges on Q4 delivery and steady Axon adoption as the holiday ad cycle peaks. [14]


Sources: company filings and releases; real‑time market pages; trade press and wire services as cited above. [15]

Disclosure: This article is for informational purposes only and does not constitute investment advice.

APP AppLovin Corporation: Q3 Profit Surge - Thursday Predicted Opening Price + 5 Price Targets 📈

References

1. www.reuters.com, 2. www.marketscreener.com, 3. digiday.com, 4. investors.applovin.com, 5. www.reuters.com, 6. www.marketscreener.com, 7. www.modernretail.co, 8. www.adexchanger.com, 9. www.reuters.com, 10. press.spglobal.com, 11. investors.applovin.com, 12. www.reuters.com, 13. www.marketscreener.com, 14. www.reuters.com, 15. investors.applovin.com

Stock Market Today

  • Noteworthy Tuesday Option Activity: CMG, CSCO, ENR Highlight Elevated Options Volume
    November 11, 2025, 6:20 PM EST. Today's notable options activity spans CMG, CSCO and ENR. CMG traded about 159,285 contracts (≈15.9 million shares), ~60% of its 1-month average daily volume. The standout is the $37.50 put expiring Dec 19, 2025 with 47,889 contracts (≈4.8 million shares). CSCO saw 100,180 contracts (≈10 million shares), about 58.2% of its 1-month average daily volume, led by the $74 call expiring Nov 14, 2025 with 25,770 contracts (≈2.6 million shares). ENR moved 4,180 contracts (≈418k shares), ~56.6% of its 1-month average. The active strikes highlighted are the $25 call expiring Dec 19, 2025 with 3,882 contracts (≈388k shares). Charts accompany each name with trailing twelve months data and strikes highlighted.
Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook
Previous Story

Pfizer (PFE) Today — Nov. 11, 2025: $10B Metsera Deal Nears Vote, Oncology Game Plan Expands, Shares Rise

Viking Therapeutics (VKTX) Rides Obesity Drug Wave: Stock Steadies as Analysts Eye Big Upside
Next Story

Viking Therapeutics (VKTX) on Nov. 11, 2025: Stifel Fireside Chat Today, Fresh VK2735 Obesity Data From ObesityWeek, and Phase 3 VANQUISH Progress

Go toTop